Details

Published: 18 April 2026

Hits: 74

Researchers have identified a common signature of how psychedelic drugs alter the brain. A landmark international study reveals that five different substances produce a remarkably similar pattern of disruption to normal brain activity.

The findings, published in Nature Medicine in April 2026, draw on more than 500 brain scans from 267 participants across five countries. This is the most comprehensive analysis to date of psychedelic drugs and the brain. Scientists pooled data from 11 independent studies examining psilocybin, LSD, DMT, mescaline and ayahuasca. They applied a uniform analytical framework to cut through years of fragmented and sometimes contradictory research.

How Psychedelic Drugs and the Brain’s Hierarchy Collide

The most striking discovery was that all five substances appear to “flatten” the brain’s natural processing hierarchy. Under normal circumstances, the brain operates along a clear gradient. Higher-order networks handle abstract thought and self-reflection. More primitive networks handle vision and basic sensation. These systems communicate in an organised, structured way.

Under the influence of psychedelics, that structure breaks down.

“All five drugs dissolve the common order, the usual hierarchy of brain systems,” said Dr Danilo Bzdok, a senior author on the study from McGill University in Montreal. “They flatten the hierarchy and that probably underlies what some people describe as this raw access to one’s own consciousness.”

The study found a sharp increase in communication between the brain’s transmodal networks and unimodal networks. Transmodal networks handle high-level thinking, including the default mode and frontoparietal networks. Unimodal networks handle vision and physical sensation. Put simply, parts of the brain that rarely talk to one another begin talking at once.

“You have an unleashed cross-talk between brain systems,” Dr Bzdok said. “They are wildly communicating with each other.”

What the Scans Revealed About Psychedelics and Brain Function

The research team, known as the BOLD Psychedelic Consortium, used resting-state functional MRI (fMRI) to measure spontaneous brain activity. They scanned participants while each substance was active. The team reprocessed all datasets through a single pipeline. They then applied a Bayesian statistical framework to measure not just whether effects existed, but how confident the findings were.

Increases in between-network connectivity were the most consistent result across all five drugs. The strongest links appeared between the default mode network and visual or sensorimotor networks.

Deeper brain structures also changed. The caudate and putamen, two striatal regions involved in habit formation, learning and movement, showed increased coupling with sensory and motor areas of the cortex. The researchers suggest this may reflect a disruption to how the brain normally filters sensory input into behaviour.

The role of the thalamus was less clear. Average brain scans suggested thalamic involvement, but the Bayesian modelling found the evidence too weak and inconsistent to support firm conclusions.

Challenging an Earlier Assumption About Psychedelic Brain Effects

One of the most consequential findings was what the study did not confirm. Several earlier papers claimed that psychedelic drugs cause widespread “disintegration” within individual brain networks. The new mega-analysis found little reliable evidence for this.

“Our results challenge previous claims of widespread within-network disintegration,” the authors wrote. Bayesian modelling showed only weak-to-moderate and selective reductions in within-network connectivity. Variability was considerable across substances and brain regions. Many apparent effects from earlier, smaller studies did not hold up under more rigorous scrutiny.

This matters because understanding psychedelics and brain function accurately is essential. It shapes how researchers and clinicians interpret what these substances actually do to a person, both immediately and over time.

Similarities and Differences Between Substances

While a shared neural fingerprint was evident, the drugs were not identical in their effects.

LSD and psilocybin produced the most similar brain changes of all five substances. This aligns with their comparable pharmacological profiles. Both work primarily by activating the 5-HT2A serotonin receptor, which sits in high concentrations in the very brain regions showing the greatest disruption.

DMT produced the most intense pattern of network disruption. However, the DMT dataset included only 16 participants, which limits firm conclusions. Ayahuasca contains DMT alongside monoamine oxidase inhibitors that alter how the body processes it. It showed the most unusual connectivity pattern of all, partly because of its distinct pharmacology and a very small sample size of just nine participants.

Mescaline fell broadly in line with psilocybin and LSD, though with a somewhat more selective pattern of effects.

Why This Study Matters

The research grew out of a widely recognised problem in this field. Despite rapid growth, psychedelic neuroscience had accumulated a confusing and contradictory body of evidence. Different laboratories used different methods with small volunteer groups and reached different conclusions.

“This field is emerging, and it is very important, but they are on shaky ground,” Dr Bzdok said. “We started the study with the ambition to provide a solid foundation.”

Dr Emmanuel Stamatakis, a senior co-author from the University of Cambridge, said the scale of coordination was itself significant. “If psychedelic research is to mature responsibly, it needs large-scale, coordinated evidence.”

The findings carry implications for clinical trials currently exploring these substances as treatments for depression, PTSD and end-of-life anxiety. A search of the clinicaltrials.gov database returns more than 400 active trials involving classic psychedelic compounds. Understanding what these drugs do to the brain is essential before any therapy can be responsibly rolled out at scale.

A Clearer Picture, With Caveats

The authors acknowledge their work has limitations. Scanner types, dosages, routes of administration and scan timing all varied across the 11 included datasets. One dataset had no placebo control group. The strong psychological effects of these substances also make true double-blind conditions very difficult to maintain.

Sample sizes varied significantly by drug. Psilocybin and LSD datasets included 106 and 119 participants respectively. DMT and ayahuasca each contributed fewer than 20. The researchers note this affects how confidently drug-specific conclusions can be drawn.

Head movement is a known problem in fMRI research. Participants under the influence of psychedelics tend to move more than usual. The team removed high-motion scans from the analysis, though some residual effects remain possible.

Taken together, the study paints a consistent picture of psychedelic drugs and the brain. Regardless of their chemical differences, these five substances temporarily reorganise large-scale brain function in a shared and identifiable way. The brain’s normal network order is suspended. Understanding exactly what that means for the people who experience it remains one of the more pressing questions in contemporary neuroscience.

The study, “An international mega-analysis of psychedelic drug effects on brain circuit function,” was published in Nature Medicine on 6 April 2026.

(Source: WRD NEWS)

Details

Published: 17 April 2026

Hits: 28

Novel benzodiazepine deaths in Australia have reached a critical threshold. New epidemiological data from the National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, documents an 87% concentration of novel benzodiazepine (NBZD) poisoning deaths within a single five-year window a mortality trajectory that directly challenges the adequacy of Australia’s harm reduction-dominant policy response. This commentary advances the position that harm reduction, as currently deployed, represents a reactive and structurally insufficient framework for a drug crisis defined by accelerating supply-side innovation, growing demand, and rising initiation rates. The data do not call for incremental expansion of downstream crisis management. They call for a fundamental reorientation of public health investment toward primary prevention and demand reduction the upstream interventions that address the conditions driving initiation before lives are lost. Managing risk is no longer sufficient. The policy priority must shift to eliminating it.

Novel Benzodiazepine Deaths in Australia: A Mortality Curve with a Direction

The findings published in Drug and Alcohol Dependence by Darke and colleagues are, by any measure, a significant public health alarm. Of 258 confirmed NBZD-related poisoning deaths recorded in Australia’s national coronial database since 2000, approximately 225 cases 87% of the total occurred between 2020 and 2025. The first recorded fatality did not appear until 2013. Within twelve years, novel benzodiazepines had moved from an emerging forensic footnote to a primary driver of drug-related mortality in this country.

A mortality curve that rises this steeply, this quickly, is not background noise. It is a signal. And the policy-relevant question it demands is not simply how to better manage the crisis at the point of harm but why the crisis reached this point while a harm reduction infrastructure was in place, and what structural reorientation is now required to change its direction.

This commentary argues that the answer lies not downstream, in expanded crisis management, but upstream, in the prevention and demand reduction frameworks that Australian drug policy has systematically deprioritised for more than a decade.

Harm Reduction as Analytical and Moral Failure

To be precise: harm reduction is not a completely failed idea, but its misapplication and misinterpretation are not only unravelling its potential for ‘reduction’ of harm, but all-to-often sustaining or increasing harms. Administered as one component within a genuinely integrated continuum of care response in the three pillars of Australia’s National Drug Strategy, has always intended harm reduction measures serve a legitimate clinical function, to keep acute harms low, whilst ensuring the drug user exits the very behaviour that is causing the harm. For example, roadside drug testing and even overdose reversal protocols can save lives. However, the ‘spinning’ of other recently introduced HR tools are undermining prevention and demand priorities, and in the case of ‘pill checking’ have increased harms, Concerningly, the evidence is not considered by certain researchers and is ignored for purposes of promoting ‘death prevention’ as the Gold Standard of drug policy. This posture alone is a significant public health and safety ‘Red Flag’. 

What is in dispute is harm reduction’s elevation to the status of a primary response strategy and the NDARC data on NBZD overdose deaths in Australia constitute a clear analytical indictment of that elevation.

Consider the evidence. Australia’s harm reduction infrastructure did not contract between 2020 and 2025. Drug checking services expanded. Overdose prevention information became more widely accessible than at any prior point. Health authorities issued 23 NBZD-related alerts over the period, with nearly half concentrated in 2025 alone. And yet the death toll from novel benzodiazepines did not plateau, stabilise, or reverse. It accelerated concentrating 87% of all recorded NBZD mortality within that same five-year window.

The analytical conclusion is unavoidable: a response framework predicated on managing risk at the point of use has proven structurally incapable of containing a drug supply that evolves faster than detection and education efforts can follow. Novel benzodiazepines are, by definition, a moving target. The 15 different NBZDs identified in the NDARC data including etizolam, bromazolam, flualprazolam, and clonazolam represent the compounds we know about. The researchers themselves acknowledge that the true extent of NBZD-related deaths likely exceeds recorded figures, given limitations in testing, data lags, and the continuous emergence of newer compounds.

Harm reduction services that respond to identified compounds are, by design, addressing yesterday’s drug. The unregulated supply chain operates under no such constraint. This is not a failure of implementation. It is a failure of strategic logic.

But the failure of harm reduction as a primary strategy is not only analytical. It is moral. A public health framework that accepts ongoing drug use as the operating condition and orients its resources around managing that use rather than reducing it has made a values choice, whether it acknowledges it or not. It has chosen to administer the consequences of a crisis rather than confront its causes. For the families who have lost someone to an NBZD overdose, that distinction is not academic. It is the difference between a system that fought to keep their loved one away from these drugs and one that was prepared to manage the outcome if they used them. Genuine care clinically, ethically, and as a matter of community responsibility means moving people away from drug use, not accommodating their continued exposure to it. Australia’s communities deserve a response built on that standard.

What the 87% Figure Actually Tells Us

The temporal concentration of novel benzodiazepine deaths in Australia is the most consequential finding in the Darke et al. dataset, and it deserves to be read as exactly what it is: a direct policy indictment.

During the period in which 87% of all recorded NBZD deaths occurred, Australia was not operating without a public health response. It was operating with one and that response was demonstrably inadequate to the scale of the problem it confronted. This is not an argument for paralysis or pessimism. It is an argument for clarity. When the data tell you the strategy is not working, the evidence-based response is to change the strategy not to scale up more of the same.

Professor Shane Darke’s observation that in two-thirds of fatal overdoses, other people were present in the immediate vicinity and that in approximately half of those cases no assistance was rendered is instructive in this regard. It is presented in the research as evidence for expanded overdose awareness training, and rightly so. But it equally represents a fundamental primary prevention failure: a population that prevention efforts had not adequately reached with accurate information about what NBZDs are, how dangerous they are, and what a life-threatening reaction looks like before exposure occurred. That is not a harm reduction gap. It is a prevention gap.

Upstream, that gap is addressable. Downstream, by the time it manifests as a death with bystanders who did not know what they were witnessing, the cost has already been paid.

The Case for Primary Prevention: Stopping NBZD Overdose Deaths in Australia Before They Start

The central analytical error of harm reduction as a governing framework is the assumption that demand cannot be meaningfully reduced that initiation will occur regardless, and that the most realistic public health objective available is minimising injury at the point of use. This assumption is not merely pessimistic. It is empirically contestable, and in the context of novel benzodiazepine deaths in Australia, it is particularly dangerous.

Unlike opioids or methamphetamine, which carry decades of established use patterns and relatively stable user populations, novel benzodiazepines are entering a market actively recruiting new users. Dr Jack Freestone’s observation that clinicians now detect NBZDs more frequently than any other novel psychoactive substance in Australian emergency department admissions and that their use is growing across survey data, hospitalisation records, and drug alert systems simultaneously confirms that we are not managing a stable population of existing users. We are watching a new drug establish itself across a broadening user base.

This distinction matters enormously for policy. If initiation is still occurring at scale, the window for preventive intervention remains open. Primary prevention directed at reducing the probability of first use through honest community education, school-based resilience programs, youth-focused social norm interventions, and the prescribing reform that addresses the pharmaceutical conditions generating demand for illicit benzodiazepine analogs can still shape the trajectory of this crisis. Once use is entrenched across a generation, that window closes, and the cost of the foregone prevention investment falls on families, communities, and the health system for decades.

A genuine upstream response to this crisis requires investment across four interlocking domains: community-wide education that reaches young people, families, and community organisations with accurate information about NBZD lethality before exposure occurs; demand reduction through resilience-building programs that reduce the underlying conditions that make drug use attractive in the first instance; prescribing reform that confronts the pharmaceutical landscape normalising benzodiazepine use and generating demand for illicit analogs; and an initiation research agenda that asks, urgently, who is using these drugs for the first time and why not simply how current users are managing their use.

Dr Freestone’s announced Navigating Novel Benzos Study, designed to understand the experiences and self-management strategies of current users, is legitimate and necessary work. But a research program anchored entirely in the behaviour of existing users cannot generate the epidemiology of initiation that a prevention-oriented response requires. The questions that will determine whether Australia’s NBZD mortality curve changes direction remain largely unanswered: who is initiating use, under what conditions, and at what point can prevention most effectively intervene?

Conclusion

The NDARC findings are a significant contribution to Australia’s understanding of a rapidly evolving drug crisis. The researchers are to be commended for the scope and rigour of their analysis. But the policy implications of their data extend well beyond the harm reduction framing that currently dominates the institutional response.

Novel benzodiazepine deaths in Australia are not the product of insufficient harm reduction. They are the product of a policy environment that has allowed harm reduction to crowd out the upstream frameworks that would reduce the population of people exposed to these drugs in the first instance. A mortality curve that concentrates 87% of its deaths in five years against a backdrop of existing harm reduction infrastructure is not a curve that is responding to its current treatment. r way out of it. We will not screen our way out of it.

The only sustainable path through a drug crisis of this velocity is to reduce the number of people who enter it. That requires prevention as the priority not the afterthought.

(Source: WRD NEWS)

This commentary reflects an independent public health policy analysis of findings published by NDARC, UNSW Sydney, on 10 March 2026. The Dalgarno Institute is one of Australia’s longest-standing community-based health education charities, working for over 150 years to minimise harm by maximising prevention. Visit dalgarnoinstitute.org.au

Details

Published: 05 November 2025

Hits: 244

The Psychedelic Syndicate: How Silicon Valley Used Veterans to Hijack the Psychedelic Industry

Excerpt from Executive Summary

This report provides an in-depth examination of how a strategic, well-funded campaign operated to influence public perception at the expense of public health.

Psymposia has spent over a year investigating the financial and political forces shaping the psychedelic industry. Through analysis of hundreds of internal documents — including unedited emails, transcripts, presentations, and other primary materials spanning nearly a decade — this report describes the rise of the Psychedelic Science Funders Collaborative (PSFC) and its extensive influence across the field.

The prevailing media narrative has characterized the psychedelic movement as an organic coalition of grassroots activists motivated by psychedelics’ therapeutic potential. Our analysis reveals PSFC's coordinated efforts to circumvent federal regulatory structures and manipulate state-level policy development, transforming a community-led movement into a vehicle for centralized corporate influence.

Following the FDA’s 2024 rejection of MDMA-assisted therapy, PSFC-funded organizations targeted critics and whistleblowers in collaboration with the Psychedelic Communications Hub (now incorporated into the Psychedelic Safety Institute). Organizations involved in this campaign included the Multidisciplinary Association for Psychedelic Studies (MAPS), Lykos Therapeutics, and veterans groups Heroic Hearts Project and Healing Breakthrough.

Having failed to subvert the FDA regulatory process, these groups are now appealing to the Trump administration to accelerate approval based on data from clinical trials characterized by serious scientific failures. Disregarding public safety concerns in their rush to bring an experimental therapy to market, PSFC responded to the FDA's rejection by intensifying strategies that would amount to regulatory capture.

View PDF

Details

Published: 23 June 2025

Hits: 502

 

Victoria is in the news seeking to open a fixed pill testing site as Pill Testing Australia operatives have shifted their focus from their ineffective and harm-escalating** pill testing narrative to one that now includes testing all manner of illicit drugs in a new operation they call ‘drug checking’.

ABC has been posting warnings about more potent opioids such as fentanyl and nitazenes, inferring that their higher potencies create higher death ratios amongst opioid users.  But Drug Free Australia demonstrates that this is most certainly untrue.  The ABC posts say, 

“Non-prescription drug overdose deaths in the ACT have doubled since the start of 2024 to 20.  Police have renewed warnings to users about the dangers of highly potent substances being increasingly detected in illicit drugs, such as fentanyl and nitazines.”

But it takes only two graphs from Australia’s official 2024 opioid overdose report to falsify this misinformation.

The first shows that deaths from the use of ALL opioids have risen at very similar rates since the 2007 Federal Government scrapped Tough on Drugs, which had kept opioid deaths at around 360 per annum between 2001 and 2007.  Deaths from all opioid types increased sharply post-2007, with deaths from the more potent Fentanyl increasing in line with the other opioids.

Just like pill testing, where Pill Testing Australia falsely** implied that most pill deaths came from other drugs or contaminants mixed into the pills, the new ‘drug checking’ narrative comes from the same playbook now used for decades in Australia.  They used to say that our masses of heroin fatalities were from criminals putting toxic contaminants in the powders or from wildly variable purities but the science demonstrated that this was simply false (p xiii).  It later emerged that just as many died from strictly uncontaminated and purity-controlled pharmaceutical opiates as from  criminal-supplied heroin, both at roughly 1% of dependent users per year.  In fact, the vast majority of opiate overdoses have had the same unifying cause – using opioids with other drugs such as alcohol and benzodiazepenes as the second graph below very clearly demonstrates.  NOTE CAREFULLY THE BOTTOM-MOST RED LINE – that is the one that includes deaths from Fentanyl alone.  And it says the very opposite of what ABC and their ilk infer.

The fact that Australian overdose reports show no major change in the ratio of polydrug-use deaths against opiates used alone suggests, despite the increased potency of Fentanyl and Nitazenes, that drug users accommodate for the increased potency of these newer substances.  When opiate deaths peaked at 1,116 in 1999, 1% of dependent heroin users were dying.  Very recent fatal overdose rates for countries with heavy Fentanyl use, which is 50 times stronger, show the same 1% dying again - pointing an accusing finger at polydrug use for BOTH opiate types.   We would expect similar user accommodation with Nitazenes which can be similar to, or stronger than Fentanyl, where weakened physiology of long-term opiate users and polydrug use are moreso causal in most fatalities.

Across Australia opiate users experience 72 non-fatal overdoses (p59) and two - three opiate fatalities per day, so these already troubling statistics can be alarmingly manipulated by media, and more made of these deaths than is warranted.   Drug Free Australia does not deny that criminal-manufactured pills with high potency opioids masquerading as lower potency opioids will cause some unexpected fatalities, but much more evidence is needed to show that these are anything but the tiny minority of fatalities.

Balanced against this are the massive number of opiate deaths caused by the harm reductionist messaging which teaches the ‘safe use of illicit drugs’, of which drug checking is seminally a part.  This messaging quadrupled opiate deaths between 1984 (below 250 for 15-44 year olds) and 1,116 for 15-54 year olds in 1999.  The prevention and rehabilitation priorities of Tough on Drugs made opiate deaths plummet by 67% (or a massive 750 opiate deaths per year), where they stayed for 7 years until a new Federal Government scrapped them.  In the decade following, with the ‘safe use of drugs’ message again prioritised, opiate deaths skyrocketed 260% with other contributing polydrug-use illicit drug deaths increasing 210-590% as can be very clearly seen in the graph above.  Harm Reduction’s ‘safe use of drugs’ ideology has very demonstrably added many, many thousands of opiate deaths to Australian mortality tolls and heavily weights any set of balances against a few lives saved by ‘drug checking’.  Drug Free Australia has no problem with law enforcement continuing to publicise contaminants or adulterants in seized drugs, maintaining the message that drug use is not acceptable, rather than allowing drug-normalisating NGOs to take that role. 

Gary Christian
PRESIDENT
Drug Free Australia
0422 163 141

This email is sent on the understanding that it is every Australian organisation’s right to inform and petition their political representatives.

** Of the 392 MDMA related deaths between mid-2000 and mid-2018 in Australia, pill testing fails to address the real causes of such pill deaths in this country.  Pill testing cannot identify those who will die from allergic-like reactions (14%), or those who will co-use ecstasy with other legal or illegal drugs (48% of deaths), or those who are accident-prone while intoxicated (29% of deaths).  There have only been 3 ‘bad batch’ deaths over those years, implicating MDMA as the drug responsible for almost every Australian ecstasy death. Yet Pill Testing GREENLIGHTS (p 11) MDMA in a pill, giving the thumbs-up to a killer drug.  This will keeping adding to our mortality toll.